This study tested a new vaccine against Group B Streptococcus bacteria in 90 healthy adults aged 55 to 75. Participants received three doses of the vaccine or a placebo and were monitored for safety and immune response for 6 months. The goal was to see if the vaccine is safe and …
Phase: PHASE1 • Sponsor: Minervax ApS • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 29, 2026 15:02 UTC